| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:54 UTC |
|---|
| HMDB ID | HMDB0015219 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Primaquine |
|---|
| Description | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) |
|---|
| Structure | COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1 InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline | ChEBI | | 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline | ChEBI | | 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline | ChEBI | | Neo-quipenyl | ChEBI | | Primachin | ChEBI | | Primachinum | ChEBI | | Primaquin | ChEBI | | Primaquina | ChEBI | | Primaquinum | ChEBI | | Kanaprim | Kegg | | Diphosphate, primaquine | MeSH | | Phosphate, primaquine | MeSH | | Primacin | MeSH | | Primaquine diphosphate | MeSH | | Primaquine phosphate | MeSH | | Boucher and muir brand OF primaquine phosphate | MeSH, HMDB |
|
|---|
| Chemical Formula | C15H21N3O |
|---|
| Average Molecular Weight | 259.3467 |
|---|
| Monoisotopic Molecular Weight | 259.168462309 |
|---|
| IUPAC Name | N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine |
|---|
| Traditional Name | N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine |
|---|
| CAS Registry Number | 90-34-6 |
|---|
| SMILES | COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1 |
|---|
| InChI Identifier | InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3 |
|---|
| InChI Key | INDBQLZJXZLFIT-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Quinolines and derivatives |
|---|
| Sub Class | Aminoquinolines and derivatives |
|---|
| Direct Parent | Aminoquinolines and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Aminoquinoline
- Methoxyaniline
- Anisole
- Alkyl aryl ether
- Secondary aliphatic/aromatic amine
- Pyridine
- Benzenoid
- Heteroaromatic compound
- Ether
- Azacycle
- Secondary amine
- Primary amine
- Organooxygen compound
- Organonitrogen compound
- Primary aliphatic amine
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Amine
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | < 25 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.056 g/L | Not Available | | LogP | 2.1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.04 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.0124 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.2 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 159.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Primaquine,1TMS,isomer #1 | COC1=CC(NC(C)CCCN[Si](C)(C)C)=C2N=CC=CC2=C1 | 2509.9 | Semi standard non polar | 33892256 | | Primaquine,1TMS,isomer #1 | COC1=CC(NC(C)CCCN[Si](C)(C)C)=C2N=CC=CC2=C1 | 2438.6 | Standard non polar | 33892256 | | Primaquine,1TMS,isomer #1 | COC1=CC(NC(C)CCCN[Si](C)(C)C)=C2N=CC=CC2=C1 | 3381.6 | Standard polar | 33892256 | | Primaquine,1TMS,isomer #2 | COC1=CC(N(C(C)CCCN)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2320.4 | Semi standard non polar | 33892256 | | Primaquine,1TMS,isomer #2 | COC1=CC(N(C(C)CCCN)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2448.8 | Standard non polar | 33892256 | | Primaquine,1TMS,isomer #2 | COC1=CC(N(C(C)CCCN)[Si](C)(C)C)=C2N=CC=CC2=C1 | 3354.3 | Standard polar | 33892256 | | Primaquine,2TMS,isomer #1 | COC1=CC(N(C(C)CCCN[Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2388.6 | Semi standard non polar | 33892256 | | Primaquine,2TMS,isomer #1 | COC1=CC(N(C(C)CCCN[Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2569.5 | Standard non polar | 33892256 | | Primaquine,2TMS,isomer #1 | COC1=CC(N(C(C)CCCN[Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2989.2 | Standard polar | 33892256 | | Primaquine,2TMS,isomer #2 | COC1=CC(NC(C)CCCN([Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2614.2 | Semi standard non polar | 33892256 | | Primaquine,2TMS,isomer #2 | COC1=CC(NC(C)CCCN([Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2617.8 | Standard non polar | 33892256 | | Primaquine,2TMS,isomer #2 | COC1=CC(NC(C)CCCN([Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 3267.2 | Standard polar | 33892256 | | Primaquine,3TMS,isomer #1 | COC1=CC(N(C(C)CCCN([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2601.2 | Semi standard non polar | 33892256 | | Primaquine,3TMS,isomer #1 | COC1=CC(N(C(C)CCCN([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2702.1 | Standard non polar | 33892256 | | Primaquine,3TMS,isomer #1 | COC1=CC(N(C(C)CCCN([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C)=C2N=CC=CC2=C1 | 2925.7 | Standard polar | 33892256 | | Primaquine,1TBDMS,isomer #1 | COC1=CC(NC(C)CCCN[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 2743.7 | Semi standard non polar | 33892256 | | Primaquine,1TBDMS,isomer #1 | COC1=CC(NC(C)CCCN[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 2611.0 | Standard non polar | 33892256 | | Primaquine,1TBDMS,isomer #1 | COC1=CC(NC(C)CCCN[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3418.9 | Standard polar | 33892256 | | Primaquine,1TBDMS,isomer #2 | COC1=CC(N(C(C)CCCN)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 2590.0 | Semi standard non polar | 33892256 | | Primaquine,1TBDMS,isomer #2 | COC1=CC(N(C(C)CCCN)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 2662.3 | Standard non polar | 33892256 | | Primaquine,1TBDMS,isomer #2 | COC1=CC(N(C(C)CCCN)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3388.7 | Standard polar | 33892256 | | Primaquine,2TBDMS,isomer #1 | COC1=CC(N(C(C)CCCN[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 2851.1 | Semi standard non polar | 33892256 | | Primaquine,2TBDMS,isomer #1 | COC1=CC(N(C(C)CCCN[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 2940.3 | Standard non polar | 33892256 | | Primaquine,2TBDMS,isomer #1 | COC1=CC(N(C(C)CCCN[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3153.4 | Standard polar | 33892256 | | Primaquine,2TBDMS,isomer #2 | COC1=CC(NC(C)CCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3054.0 | Semi standard non polar | 33892256 | | Primaquine,2TBDMS,isomer #2 | COC1=CC(NC(C)CCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 2954.1 | Standard non polar | 33892256 | | Primaquine,2TBDMS,isomer #2 | COC1=CC(NC(C)CCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3345.3 | Standard polar | 33892256 | | Primaquine,3TBDMS,isomer #1 | COC1=CC(N(C(C)CCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3270.1 | Semi standard non polar | 33892256 | | Primaquine,3TBDMS,isomer #1 | COC1=CC(N(C(C)CCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3203.1 | Standard non polar | 33892256 | | Primaquine,3TBDMS,isomer #1 | COC1=CC(N(C(C)CCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2N=CC=CC2=C1 | 3163.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Primaquine GC-MS (Non-derivatized) - 70eV, Positive | splash10-001l-7390000000-20feb8c491df9e9e6f0d | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Primaquine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Primaquine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-qTof , Positive-QTOF | splash10-01r6-0970000000-a3b1021cda642a6141b8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-01p6-4290000000-d5f33ea098bbcd333ccf | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-000l-9360000000-9f32d7ddbda48f0e2dc5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-002r-9530000000-5c70a8800c55df1915e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-002r-9810000000-89e3b0e2b3cb4d1e9293 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-00n0-5900000000-cbe196964f610f8bf1ff | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-00o9-3900000000-6209d7be74ea608e7fc2 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QTOF , positive-QTOF | splash10-03di-0190000000-32ab0ba382901a73b1c0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QTOF , positive-QTOF | splash10-002f-1690000000-82416f4c3f338eece150 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QTOF , positive-QTOF | splash10-004i-0920000000-65f7b4135f0db6eee15e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QTOF , positive-QTOF | splash10-004i-0900000000-17b7474db1209213f689 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QTOF , positive-QTOF | splash10-001i-0900000000-b2c7e131a6a25d115853 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine , positive-QTOF | splash10-01r6-0970000000-a3b1021cda642a6141b8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-001i-2900000000-d3dfd1b72d458ffd07d7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-01p6-4290000000-314f515d08e6730a1df9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-000l-9360000000-3933ab4d9c2c3918ecce | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-002r-9530000000-65625d68f98ae8f36ea0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine LC-ESI-QFT , positive-QTOF | splash10-002r-7910000000-6c3e274b81107c5e98eb | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Primaquine 30V, Positive-QTOF | splash10-000l-9360000000-239fc11ba8db0d498ff2 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Primaquine 10V, Positive-QTOF | splash10-03dl-0090000000-045cb60c1f5b86235b8d | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Primaquine 20V, Positive-QTOF | splash10-0296-4290000000-01a4b9c14070fa4302c3 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Primaquine 40V, Positive-QTOF | splash10-0006-9730000000-42103ce07831ca6222a5 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Primaquine 10V, Negative-QTOF | splash10-0a4i-0090000000-1af4abbe157a64d54565 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Primaquine 20V, Negative-QTOF | splash10-0a4i-1290000000-d23ff1647c1e20943a1c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Primaquine 40V, Negative-QTOF | splash10-006x-2930000000-c2b4d4e6f2d8325f4a71 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM: Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol. 1985 Jun;19(6):745-50. [PubMed:4027117 ]
- Cohen RJ, Sachs JR, Wicker DJ, Conrad ME: Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med. 1968 Nov 21;279(21):1127-31. [PubMed:5686480 ]
- Coleman MD, Coleman NA: Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996 Jun;14(6):394-405. [PubMed:8828017 ]
- ALVING AS, ARNOLD J, HOCKWALD RS, CLAYMAN CB, DERN RJ, BEUTLER E, FLANAGAN CL: Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955 Aug;46(2):301-6. [PubMed:13242948 ]
- Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006 Sep;75(3):402-15. [PubMed:16968913 ]
|
|---|